{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:46:52Z","timestamp":1774122412688,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1378\/chest.130.6.1712","type":"journal-article","created":{"date-parts":[[2006,12,13]],"date-time":"2006-12-13T13:31:20Z","timestamp":1166016680000},"page":"1712-1717","source":"Crossref","is-referenced-by-count":94,"title":["Enhancement of Treatment Completion for Latent Tuberculosis Infection With 4 Months of Rifampin"],"prefix":"10.1016","volume":"130","author":[{"given":"Alfred","family":"Lardizabal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Passannante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faysal","family":"Kojakali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee B.","family":"Reichman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1378\/chest.130.6.1712_bib1","first-page":"245","article-title":"Trends in tuberculosis: United States, 2004","volume":"54","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1378\/chest.130.6.1712_bib2","first-page":"S221","article-title":"American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.130.6.1712_bib3","article-title":"Ending neglect: the elimination of tuberculosis in the United States","year":"2000"},{"key":"10.1378\/chest.130.6.1712_bib4","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1001\/jama.1991.03460220075035","article-title":"Isoniazid as preventive therapy in HIV infected intravenous drug abusers","volume":"265","author":"Jordan","year":"1991","journal-title":"JAMA"},{"key":"10.1378\/chest.130.6.1712_bib5","article-title":"International Union Against Tuberculosis and Lung Disease","year":"2004","journal-title":"Anti-tuberculosis drug resistance in the world: report No. 3"},{"key":"10.1378\/chest.130.6.1712_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","author":"Lo Bue","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.130.6.1712_bib7","year":"2006","journal-title":"Dear colleague letter from Dr. Kenneth Castro, Director, Division of Tuberculosis Elimination"},{"key":"10.1378\/chest.130.6.1712_bib8","first-page":"735","article-title":"Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2014United States, 2003","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1378\/chest.130.6.1712_bib9","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMcp021045","article-title":"Latent tuberculosis infection","volume":"347","author":"Jasmer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.130.6.1712_bib10","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.200405-584PP","article-title":"Considering the role of four months of rifampin in the treatment of latent tuberculosis infection","volume":"170","author":"Reichman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.130.6.1712_bib11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.130.6.1712_bib12","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1164\/ajrccm\/140.5.1189","article-title":"Experimental short course chemotherapy with rifampin and pyrazinamide","volume":"140","author":"Lecoeur","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.130.6.1712_bib13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/AAC.40.3.552","article-title":"Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide","volume":"40","author":"Dhillon","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1378\/chest.130.6.1712_bib14","first-page":"36","article-title":"Hong Kong Chest Service, Tuberculosis Research Centre, Madras, and BMJ Research Council. 1992. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong","volume":"145","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.130.6.1712_bib15","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1164\/ajrccm.154.5.8912767","article-title":"Rifampin preventive therapy for tuberculosis in Boston\u2019s homeless","volume":"154","author":"Polesky","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.130.6.1712_bib16","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1164\/ajrccm.155.5.9154885","article-title":"Rifampin preventive therapy for tuberculosis infection","volume":"155","author":"Villarino","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.130.6.1712_bib17","first-page":"652","article-title":"Tuberculosis","year":"2003","journal-title":"Red Book: 2003; Report of the Committee on Infectious Diseases"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236921550891X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236921550891X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T18:56:31Z","timestamp":1555959391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001236921550891X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S001236921550891X"],"URL":"https:\/\/doi.org\/10.1378\/chest.130.6.1712","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}